TITLE:
Clinical and Treatment Characteristics of Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Advanced Ovarian and Primary Peritoneal Cancer: A Retrospective Single-Center Study
AUTHORS:
Ishfaq Beenish, Mehwish Mehwish, Nan Zhang, Sicong Liu, Xiaoyuan Lu, Wenyu Mu, Buze Chen, Shuang Shi
KEYWORDS:
Advanced Ovarian Cancer, Primary Peritoneal Carcinoma, Cytoreductive Surgery, Hyperthermic Intraperitoneal Chemotherapy, Peritoneal Cancer Index, Completeness of Cytoreduction
JOURNAL NAME:
Open Journal of Obstetrics and Gynecology,
Vol.16 No.10,
October
15,
2026
ABSTRACT: In selected patients with advanced or recurrent ovary and primary peritoneal cancer, cytoreductive surgery with hyperthermic intraperitoneal chemotherapy is performed. Institutional data on the clinical features, treatment patterns, and completeness of cytoreduction in patients who have received this treatment, however, are limited. In this study, the disease and treatment characteristics of patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy at a single specialist center were described. This is a single-center, retrospective, descriptive study that involved 40 women with epithelial ovarian or primary peritoneal cancer (Stages III-IV) who underwent cytoreductive surgery (CS) and hyperthermic intraperitoneal chemotherapy (HIPEC) from January 2019 to July 2024. Data on age, FIGO stage, tumour location, histopathology, Peritoneal Cancer Index, neoadjuvant chemotherapy, indication of hyperthermic intraperitoneal chemotherapy, and completeness of cytoreduction were obtained. Means and standard deviations were used for continuous variables and frequencies and percentages were used for categorical variables. Mean age was 48.5 ± 11.8 years; mean Peritoneal Cancer Index 10.9 ± 3.7. The majority of patients (72.5%) had FIGO stage III disease and 11 patients (27.5%) had stage IV disease. The primary tumour was ovarian in 32 patients (80.0%) and primary peritoneal in eight patients (20.0%). Twenty-two patients (55.0%) received neoadjuvant chemotherapy. The most common histological type was high grade serous carcinoma (17 cases, 42.5%). In 16 patients (40.0%) primary cytoreductive surgery was combined with hyperthermic intraperitoneal chemotherapy. Of the 40 patients, 20 (50.0%) had complete cytoreduction (CC-0), 18 (45.0%) had CC-1 residual disease and two (5.0%) had CC-2 residual disease. This retrospective analysis provides the clinical and treatment characteristics of a subset of patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Complete macroscopic cytoreduction (CC-0) was achieved in 50.0% of patients, while 95.0% had CC-0 or CC-1 residual-disease status and were diagnosed with FIGO stage III disease. Findings are descriptive and do not imply any statements about the safety of treatment, postoperative morbidity, relative effectiveness or survival.